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Abstract
Background: Estrogens are crucial tumorigenic hormones, which impact the cell growth and
proliferation during breast cancer development. Estrogens are metabolized by a series of enzymes
including COMT, which converts catechol estrogens into biologically non-hazardous
methoxyestrogens. Several studies have also shown the relationship between estrogen and cell
cycle progression through activation of CCND1 transcription.
Methods:  In this study, we have investigated the independent and the combined effects of
commonly occurring CCND1 (Pro241Pro, A870G) and COMT (Met108/158Val) polymorphisms
to breast cancer risk in two independent Caucasian populations from Ontario (1228 breast cancer
cases and 719 population controls) and Finland (728 breast cancer cases and 687 population
controls). Both COMT and CCND1 polymorphisms have been previously shown to impact on the
enzymatic activity of the coded proteins.
Results: Here, we have shown that the high enzymatic activity genotype of CCND1High (AA) was
associated with increased breast cancer risk in both the Ontario [OR: 1.3, 95%CI (1.0–1.69)] and
the Finland sample [OR: 1.4, 95%CI (1.01–1.84)]. The heterozygous COMTMedium (MetVal) and the
high enzymatic activity of COMTHigh (ValVal) genotype was also associated with breast cancer risk
in Ontario cases, [OR: 1.3, 95%CI (1.07–1.68)] and [OR: 1.4, 95%CI (1.07–1.81)], respectively.
However, there was neither a statistically significant association nor increased trend of breast
cancer risk with COMTHigh (ValVal) genotypes in the Finland cases [OR: 1.0, 95%CI (0.73–1.39)].
In the combined analysis, the higher activity alleles of the COMT and CCND1 is associated with
increased breast cancer risk in both Ontario [OR: 2.22, 95%CI (1.49–3.28)] and Finland [OR: 1.73,
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95%CI (1.08–2.78)] populations studied. The trend test was statistically significant in both the
Ontario and Finland populations across the genotypes associated with increasing enzymatic activity.
Conclusion: Using two independent Caucasian populations, we have shown a stronger combined
effect of the two commonly occurring CCND1 and COMT genotypes in the context of breast
cancer predisposition.
Background
Estrogen demonstrates diverse effects in humans and has
a critical role in breast cancer development. Estrogen
exerts its effect by simultaneously stimulating the tran-
scription of genes, via the estrogen receptor, necessary for
cell proliferation and by causing DNA damage via their
catechol estrogen metabolites [1,2]. The two major estro-
gens, 17B-estradiol (E2) and estrone (E1), are oxidized to
the 2-OH and 4-OH catechol estrogens and 16-a hydrox-
yestrogen by CYP1A1 and CYP1B1 [3,4]. The toxic metab-
olites of these phase I enzymes are detoxified through
methylation, sulfonation and gluconation. Catechol-O-
methyl transferase (COMT), the phase II enzyme, cata-
lyzes the catechol estrogens into methoxyestrogens.
COMT is constitutively expressed mainly in brain, liver
and kidney, but also in peripheral tissue, including the
epithelial cells in the ducti and lobuli of normal mam-
mary. Most detoxification happens in the liver, but it takes
place in peripheral tissues as well, including breast [5].
COMT expression is elevated in tumor tissue compared to
normal mammary tissue [6]. COMT activity varies among
individuals, and lower activity is associated with low ther-
mal stability [7,8]. A commonly occurring single nucle-
otide polymorphism (SNP) in the 108/158th amino acid
of the COMT protein sequence results in two different
alleles of COMT (A to G change at position 1947; rs4680),
COMT (Met) and COMT (Val). It has been suggested that
COMTLow (Met) may have 3 to 4-fold less enzymatic activ-
ity compared to COMTHigh (Val) [9,10].
Estrogen is also major regulator of cell cycle progression in
breast cancer cells [11]. Several studies have shown the
relationship between estrogen and cell cycle progression
through activation of CCND1 transcription [12,13].
CCND1 is the key regulator of transition of the cell from
G1 to its proliferative S phase. CCND1 accumulates and
activates CDK4/6 in response to mitogenic growth factors
in early to mid G1 phase, and initiates the transcription of
transcription factors required in the subsequent S phase.
Excess accumulation of CCND1 in a cell due to either
amplification of CCND1 gene or over-expression of its
protein product has been frequently found in various can-
cers, including breast cancer [14]. With respect to the
genetic variants of CCND1, it is suggested that a com-
monly occurring G to A substitution at position 6962
(rs603965) (Pro241Pro) in exon 4 produces two alterna-
tively spliced forms of transcript. Splicing form CCND1b
produced by the CCND1 (A) allele lacks exon 5 [15]. This
last exon contains a rapid protein degradation motif
(PEST), and the protein product of the CCND1High (A)
allele is hypothesized to be more stable compared to the
product of CCND1Low (G) allele [15]. It also has been
observed that splicing form lacking exon 5, thus lacking a
phosphorylated Thr residue (Thr286), is unable to be
transported to cytoplasm and unable to be ubiquitinated
[16,17] and is a nuclear oncogene [18].
In our previous study [19], we examined the breast cancer
risk associated with interactions among the SNPs of genes
involved in major cancer related pathways. Multivariate
analyses revealed several statistically significant SNP-SNP
interactions associated with increased breast cancer risk
including one between CCND1 Pro241Pro and COMT
Met108/158Val polymorphisms. In this study we have
studied the combined effects of CCND1 and COMT poly-
morphisms in the expanded version of the original study
population from Ontario, Canada. Additionally, we have
also included an independent population from Finland to
validate our findings. This study further supports the com-
bined role of CCND1 and COMT genotypes in breast sus-
ceptibility.
Methods
Subject Populations
Ontario Population
(i) Case-subjects (n = 1228), were women with patholog-
ically confirmed diagnoses of breast cancer, between 1996
and 1998 were identified through the Ontario Cancer
Registry and recruited into the Ontario Familial Breast
Cancer Registry (OFBCR), a participating site in the US
NIH Breast Cancer Family Registry (BCFR) [20,21]. Sev-
enty three percent (n = 894) of all cases represented
women at increased risk of genetically-related breast can-
cer based on the following criteria: Ashkenazi Jewish
background; diagnosed before age 36 years; previous
ovarian or breast cancer diagnosis; one or more first- or
two or more second-degree relatives with breast or ovar-
ian cancer; one or more second- or third-degree relatives
with either breast cancer diagnosed before age 36 years,
ovarian cancer diagnosed before age 61 years, multiple
breast or breast and ovarian primaries, or male breast can-
cer; or three or more first-degree relatives with any combi-
nation of breast, ovarian, colon, prostate, or pancreatic
cancer or sarcoma, with at least one diagnosis before ageBMC Cancer 2008, 8:6 http://www.biomedcentral.com/1471-2407/8/6
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51 years were included in the study. In Ontario sample,
35.6% (437/1228) of breast cancer cases had one or more
first degree relatives with breast or ovarian cancers. The
age range of all participating women was 25–69 years,
with an average of 48.8 ± 9.26 years. (ii) Population con-
trols (n = 719) were also resourced from the OFBCR.
These controls were recruited by calling randomly selected
residential telephone numbers from across the province
of Ontario and were frequency-matched to all female
OFBCR cases by 5-year age group. The reference age range
of population control samples from OFBCR is 23–69 with
an average of 49.1 ± 9.55 years. More information regard-
ing the selection and recruitment of cases is given else-
where [20,21]. Written informed consent was obtained
from all subjects, and the study protocol was approved by
Mount Sinai Hospital Research Ethics Board.
Finnish Population
(i) Case-subjects (n = 728) were unselected for family
history, and treated in Helsinki University Central Hospi-
tal during 1997–1998 [22], and 2000 [23]. Of these cases
73% (n = 534) are sporadic cases without a family history
of breast or ovarian cancer, and 27% (n = 194) had a fam-
ily history with at least one or more first degree relatives
with breast or ovarian cancer. The reference age range of
all Finland cases is 22–69, with an average age of 53.2 ±
9.34. (ii) Population controls (n = 687) are healthy indi-
viduals collected from the same geographical region. The
number of the controls was 920 originally, with an age
range of 18–65. In order to match the age distribution in
Finland and Ontario control samples all of the samples in
the age range of 18–20 (n = 52) were excluded, and ran-
domly selected 10% of the samples were included in the
age range of 21 to 30, thus excluding the 90% (n = 181)
of the controls in this group. The age range of control sam-
ples in the final list (n = 687) was 21–65, with an average
of 47.1 ± 10.12 years.
Molecular Genotyping
As described previously [19], the genotyping of Ontario
breast cancer and population control DNA specimens for
both CCND1 and COMT SNPs were performed by Taq-
Man 5'nuclease assay [24] using the ABI PRISM 7900 HT
Sequence Detection System (version 2.0). The genotyping
of the Finnish DNA samples from the breast cancer cases
and population controls was done using Amplifluor fluo-
rescent genotyping (K-Biosciences, Cambridge, United
Kingdom), as described previously [25]. The reliability of
the results was determined by re-genotyping a randomly
selected 10% portion of the total study population.
Statistical Analysis
At the first stage, we calculated crude allele and genotype
frequencies for both individual polymorphisms and eval-
uated Hardy-Weinberg equilibrium using a one-degree of
freedom Pearson's goodness-of-fit test among controls.
The association between each the case-control status and
each individual SNP was measured by the odds ratio (OR)
and its corresponding 95% confidence interval. All analy-
ses were performed assuming a dominant and recessive
effects for each polymorphism, and the results presented
here are crude analysis results. The alleles of both CCND1
and COMT previously associated with a lower enzymatic
activity in the control population were used as reference
group both in individual and combined SNP association
analyses. The power computation was performed with the
genetic software QUANTO [26].
To detect trends from the CCND1 and COMT interactions
in breast cancer cases from Ontario and Finland popula-
tions, we applied the Trend Analysis Program from the
PEPI computer software package (Sagebrush Press, Salt
Lake City) [27]. Trend analysis is based on the chi-square
test for association in which the data have a natural order-
ing [28].
Selection of Studies, Data Extraction and Meta-Analysis
We searched for all studies that reported an association
between COMT (Met108/158Val) polymorphism and
breast cancer risk using the PubMed electronic database.
The following search terms and their combinations were
used: "COMT", "breast cancer" and "polymorphism".
Additional studies were manually searched in the refer-
ence list of all identified publications. Studies were
included if the genotypic data provided could be used to
calculate an odds ratio (OR) and corresponding 95% con-
fidence interval (95% CI). We examined overall associa-
tion of the variant genotype of COMT and breast cancer
by estimating the risk of the homozygous genotype GG
using the common genotype AA as reference. Pooled ORs
were obtained using the fixed [29] (Mantel-Haenszel) and
random [30] (DerSimonian-Laird) effects models. Assum-
ing genuine diversity in the results of various studies,
between study variance is incorporated with the random
effects model, which was used in the presence of hetero-
geneity [30]. In its absence, the fixed effects model was
used [29]. Heterogeneity between studies was estimated
using the χ2-based Q test [31] and quantified with the I2
statistic which provides an estimate of how much hetero-
geneity is unlikely to be due to chance [32]. A P value of
0.05 was used throughout except in heterogeneity estima-
tion which was set at P < 0.10 [33]. Data were analyzed
using Review Manager (RevMan, version 4.2, The
Cochrane Collaboration, Oxford, England) and Sigma-
Plot (version 9.01).BMC Cancer 2008, 8:6 http://www.biomedcentral.com/1471-2407/8/6
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Results
Independent Analysis of CCND1 and COMT 
Polymorphisms
Here we have investigated the independent and combined
association of CCND1 Pro241Pro and COMT Met108/
158Val polymorphisms using a case control design from
two independent populations of Ontario (1228 cases and
719 controls) and Finland (728 cases and 687 controls).
The mean age of Ontario cases and controls were 48.8 ±
9.26 and 49.1 ± 9.55, and the mean age of Finland cases
and controls were 53.2 ± 9.34 and 47.1 ± 10.12, respec-
tively.
The allele frequencies of COMT and CCDN1 polymor-
phisms were very similar in the control group of both
populations. The minor allele frequencies are 0.45 and
0.47 for COMTHigh  (Val), and 0.46 and 0.46 for
CCND1High (A), in Finland and Ontario control popula-
tions, respectively. The allele frequencies for COMT and
CCDN1 polymorphisms in the breast cancer populations
of both Finland and Ontario was 0.45 and 0.51 for
COMTHigh(Val), and 0.50 and 0.49 for CCND1High (A),
respectively. Any possible deviation from HWE was evalu-
ated by Pearson's goodness-of-fit chi-square test. No devi-
ation was observed for any of the SNPs in either
populations as shown by the p  values for controls in
Ontario (COMT, p = 0.83 and CCND1, p = 0.42), and Fin-
land (COMT, p = 0.67 and CCND1, p = 0.99).
We observed that the potentially high enzymatic activity
CCND1High (AA) genotype was associated with increased
breast cancer risk in both the Ontario [OR: 1.3, 95%CI
(1.0–1.69)] and the Finland sample [OR: 1.4, 95%CI
(1.01–1.84)] (Table 1). The heterozygous COMTMedium
(MetVal) and the high enzymatic activity of COMTHigh
(ValVal) genotype was also associated with breast cancer
risk in Ontario cases, with an OR of 1.3, 95%CI (1.07–
1.68) and 1.4, 95%CI (1.07–1.81), respectively. However,
there was no statistically significant association or
increased trend of breast cancer risk with COMTHigh (Val-
Val) genotypes in the Finland cases [OR: 1.0, 95%CI
(0.73–1.39)].
In order to assess the association of COMT genotypes with
breast cancer risk, we have carried out a meta-analysis.
Thirteen studies provided genotype data from 6,809 cases
and 6,190 controls for the COMT Met108/158Val poly-
morphism [19,34-43]. Overall fixed-effects for pooled OR
were slightly increased but was not statistically significant
for GG vs. AA comparison [OR: 1.08, 95% CI (0.93–1.24),
p = 0.32] with moderate heterogeneity [GG vs. AA: Phetero-
geneity = 0.06; I2 = 41%] (Figure 1a). Since the genotype dis-
tribution of the control population in two studies [41,43]
deviated from the HWE, we have repeated the meta-anal-
ysis after removing these studies. This has demonstrated
statistically significant association with breast cancer risk
for GG vs. AA comparison, [OR: 1.14, 95% CI (1.03–
1.26), p = 0.01] with no heterogeneity [GG vs. AA: Phetero-
geneity = 0.58; I2 = 0%] (Figure 1b).
Approximately 9% of the breast cancer cases and 3% of
the controls in the Ontario sample were of Ashkenazi Jew-
ish background. In order to assess whether this introduced
an ethnicity bias to our findings, we have re-tested the
sample after removing these individuals, where we did
not see any difference in the associations (results not
shown).
Combined Analysis of CCND1 and COMT Polymorphisms
The association of the combined CCND1 and COMT gen-
otypes was also tested and the results are presented after
grouping the genotypes according to their level of enzy-
matic activity (Table 2). The low enzymatic activity geno-
type combinations of CCND1 and COMT (CCND1Low/
COMTLow) were taken as a reference compared to the
medium (heterozygote combinations) and high activity
(CCND1High/COMTMedium  and CCND1High/COMTHigh)
combinations. In Ontario, the heterozygote (medium
activity) [OR: 1.66, 95%CI (1.18–2.33)] and high activity
[OR: 2.22, 95%CI (1.49–3.28)] combinations of CCND1
and COMT genotypes showed statistically significant
association with increased breast cancer risk. In Finland,
the high activity genotype combinations (CCND1High/
COMTHigh and CCND1High/COMTMedium) were also signif-
icantly associated with increased breast cancer risk [OR:
1.73, 95%CI (1.08–2.78)]. The medium activity combina-
tions in Finland sample followed a trend of increased
breast cancer risk [OR: 1.21, 95%CI (0.81–1.83)], but did
not reach statistical significance. The trend test was statis-
tically significant in both the Ontario (χ2
trend = 14.62, df =
1, p = 0.00013) and Finland (χ2
trend = 6.30, df = 1, p =
0.012) populations across the genotypes associated with
increasing enzymatic activity. We have also investigated
the COMT and CCND1 genotype interactions by age,
familial status and ER subgroups; however we did not
observe any differences from the overall analysis (data not
shown).
The study in Ontario was designed to reach 80% power to
detect an odds-ratio (OR) of about 2.1 for the interaction
assuming a recessive model for CCND1 and a dominant
model for COMT using a two-sided test. Although the
study in Finland enrolled less cases and controls than in
Ontario, this study achieved almost the same power
assuming we know the direction of the effect and we can
use a one-sided test. This can be justified in a replication
study.B
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Table 1: Characterization of the main effects of CCND1 and COMT polymorphisms in Ontario and Finland cases.
ONTARIO FINLAND
CCND1 Activity Genotype Controls N (%) Cases N (%) OR 95% CI Controls N (%) Cases N (%) OR 95% CI
CCND1Low GG 217 (30.2) 335 (27.4) 1 - 195 (29) 179 (25.1) 1 -
CCND1Medium AG 346 (48.1) 573 (46.9) 1.1 0.86–1.33 334 (49.7) 355 (49.8) 1.2 0.9–1.49
CCND1High AA 156 (21.7) 314 (25.7) 1.3 1.01–1.69 143 (21.3) 179 (25.1) 1.4 1.01–1.84
CCND1Medium/CCND1High AG/AA 502 (69.8) 887 (72.6) 1.15 0.93–1.4 477 (71) 534 (74.9) 1.22 0.96–1.55
Total 719 1222 672 713
ONTARIO FINLAND
COMT Activity Genotype Controls N (%) Cases N (%) OR 95% CI Controls N (%) Cases N (%) OR 95% CI
COMTLow AA (MetMet) 201 (28.2) 273 (22.4) 1 - 168 (30.60) 206 (29.10) 1 -
COMTMedium AG (MetVal) 353 (49.5) 642 (52.8) 1.3 1.07–1.68 267 (48.63) 361 (50.99) 1.1 0.85–1.43
COMTHigh GG (Val) 160 (22.4) 302 (24.8) 1.4 1.07–1.81 114 (20.77) 141 (19.92) 1 0.73–1.39
COMTMedium/COMTHigh AG (MetVal)/GG(ValVal) 513 (71.9) 944 (77.6) 1.36 1.1–1.67 381 (69.4) 502 (70.91) 1.1 0.85–1.37
Total 714 1217 549 708BMC Cancer 2008, 8:6 http://www.biomedcentral.com/1471-2407/8/6
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The risk estimates (OR) of COMTHigh (Val) allele Figure 1
The risk estimates (OR) of COMTHigh (Val) allele. a) Meta-analysis of reported case control studies in Caucasian breast 
cancer samples and population controls. b) Meta-analysis of reported case control studies in Caucasian breast cancer samples 
and population controls (which are in agreement with HWE).
a.
more in controls 1
Total (95% CI)
Sazci et al [41] TUR
Akisik et al [35] TUR
Lavigne et al [38] USA
Kocabas et al [37] TUR
Onay et al [this study] FIN
Wedren et al [42] SWE
Thompson et al [43] USA
Ahsan et al [34] USA
Gaudet et al [36] USA
Millikan et al [39] USA
Mitrunen et al [40] FIN
Onay et al [19] 2006
Onay et  al [this study] ONT
more in cases
OR (random)       
95% CI
Case n/N Control n/N
Weight 
(%)
1.39 [1.07 - 1.81] 302 / 575 160 / 361 12.36
1.30 [0.87 - 1.96] 102 / 196 80 / 176 7.80
1.28 [0.90 - 1.84] 115 / 243 100 / 243 9.12
1.23 [0.83 - 1.83] 103 / 205 86 / 191 8.12
1.15 [0.90 - 1.46] 287 / 527 277 / 543 13.34
1.12 [0.62 - 2.02] 46 / 88 44 / 89 4.62
1.06 [0.71 - 1.59] 69 / 197 78 / 232 8.01
1.06 [0.86 - 1.31] 290 / 743 289 / 768 14.75
1.01 [0.73 - 1.39] 141 / 347 114 / 282 10.33
0.74 [0.30 - 1.83] 28 / 42 35 / 48 2.24
0.69 [0.33 - 1.45] 21 / 56 27 / 58 3.13
0.69 [0.32 - 1.47] 29 / 55 34 / 55 3.05
0.30 [0.14 - 0.64] 33 / 61 62 / 78 3.14
1.08 [0.93 - 1.24] 3335 3124 100.00
       Total events: 1566 (cases), 1386 (controls)
       Test for heterogeneity: x
2 = 20.3, df = 12 (P = 0.06) I
2 = 41%
       Test for overall effect: Z = 0.99 (P = 0.32)
b.
more in controls 1
Total (95% CI)
Akisik et al [35] TUR
Lavigne et al [38] USA
Kocabas et al [37] TUR
Onay et al [this study] FIN
Wedren et al [42] SWE
Ahsan et al [34] USA
Gaudet et al [36] USA
Millikan et al [39] USA
Mitrunen et al [40] FIN
Onay et al [19] 2006
Onay et  al [this study] ONT
more in cases
OR (random)          
95% CI
Case n/N Control n/N Weight (%)
1.39 [1.07 - 1.81] 302 / 575 160 / 361 13.36
1.30 [0.87 - 1.96] 102 / 196 80 / 176 5.47
1.28 [0.90 - 1.84] 115 / 243 100 / 243 7.54
1.23 [0.83 - 1.83] 103 / 205 86 / 191 6.34
1.15 [0.90 - 1.46] 287 / 527 277 / 543 17.79
1.12 [0.62 - 2.02] 46 / 88 44 / 89 2.99
1.06 [0.86 - 1.31] 290 / 743 289 / 768 24.81
1.01 [0.73 - 1.39] 141 / 347 114 / 282 10.69
0.74 [0.30 - 1.83] 28 / 42 35 / 48 1.56
0.69 [0.33 - 1.45] 21 / 56 27 / 58 2.37
0.69 [0.32 - 1.47] 29 / 55 34 / 55 2.30
1.14 [1.03 - 1.26] 3077 2814 100.00
       Total events: 1464 (cases), 1246 (controls)
       Test for heterogeneity: x
2 = 8.5, df = 10 (P = 0.58) I
2 = 0%
       Test for overall effect: Z = 2.5 (P = 0.01)B
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Table 2: CCND1.COMT interaction in breast cancer cases from Ontario and Finland populations.
ONTARIO FINLAND
Combined Enzymatic 
Activity
Combined 
Genotype
Controls N (%) Cases N (%) OR CI Controls N (%) Cases N (%) OR CI
CCND1Low/COMTLow GGAA 73 (10.2) 74 (6.1) 1.0 - 51 (9.4) 52 (7.4) 1.0 -
CCND1Low/COMTMedium, 
CCND1Low/COMTHigh, 
CCND1Medium/COMTMedium, 
CCND1Medium COMTLow, 
CCND1Medium COMTHigh, 
CCND1High/COMTLow
GGAG, GGGG, 
AGAG, AGAA, 
AGGG, AAAA
534 (74.4) 897 (73.6) 1.66 1.18–2.33 416 (76.6) 515 (73.4) 1.21 0.81–1.83
CCND1High/COMTMedium, 
CCND1High/COMTHigh
AAAG, AAGG 107 (14.9) 240 (19.8) 2.22 1.49–3.28 76 (14) 134 (19.1) 1.73 1.08–2.78
Total 714 1211 543 701
Trend Test p = 0.00013 p = 0.012BMC Cancer 2008, 8:6 http://www.biomedcentral.com/1471-2407/8/6
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Discussion
In this study, we have investigated the contribution of
independent and the combined effects of CCND1
Pro241Pro and COMT Met108/158Val polymorphisms to
breast cancer risk in two independent Caucasian popula-
tions from Ontario and Finland. Both CCND1 and COMT
polymorphisms have been previously shown to have an
impact on the function of the protein products, altering
their overall enzymatic activity in the cell. The protein
product encoded by the COMTHigh (Val) allele has been
suggested to be 3 to 4-fold more active compared to the
COMTHigh (Val) allele. Also, the protein encoded by the
CCND1High (A) allele has also been hypothesized to pro-
duce a more stable protein compared to the CCND1Low
(G) allele. Both COMT and CCND1 polymorphisms
occur frequently in the population controls studied. The
frequency of CCND1High (AA) genotype was 21.7% and
21.3%, whereas the COMTHigh  (ValVal) genotype was
22.4% and 20.8 % in Ontario and Finland control popu-
lations, respectively.
Analysis of the independent contribution of the CCND1
polymorphism to breast cancer risk has shown a statisti-
cally significant association with increased breast cancer
risk in both Ontario and Finland. To date a total of three
studies with relatively small sample sizes (with a range of
~200–500 cases) have examined the contribution of the
CCND1 polymorphism to breast cancer risk; however
none of them has shown statistically significant associa-
tion with breast cancer risk [44-46]. Thus, our study is the
first to show the statistically significant association of the
CCND1 polymorphism with breast cancer in two inde-
pendent, relatively large case control studies.
Analysis of the independent contribution of COMT poly-
morphism has also shown a statistically significant associ-
ation between the COMTHigh  (ValVal) genotypes and
increased breast cancer risk in Ontario but not in Finland
sample. As summarized in Figure 1, meta-analysis of
reported case control studies in Caucasian breast cancer
samples and non-cancer controls have shown statistically
significant association of COMTHigh  (ValVal) genotype
with breast cancer risk [19,34-43]. The literature suggests
a protective role for COMTHigh (Val) enzymatic activity
which includes the conversion of the catechol estrogens
into their proper methoxyestrogens. This activity reduces
the chance of DNA damage caused by reactive oxygen spe-
cies that are created by oxidation of estrogen. However, a
recent study reported a non-competitive negative feed-
back inhibition of CYP1A1 and CYP1B1 enzymes by
methoxyestrogens [47]. According to their findings meth-
oxyestrogens generated by COMT inhibit oxidation of the
parent estrogen by CYP1A1 and CYP1B1. In addition,
although one of the metabolites of COMT, namely 2-
methoxyestrogen, is found to protect the tissues from can-
cer by inhibiting angiogenesis [2], the same product was
also found to cause chromosome breaks and aneuploidy
at increased concentrations [48], suggesting a delicate bal-
ance of concentrations of any metabolites or enzymes in
the estrogen metabolism. Thus these evidences support
the role of high COMT activity in breast cancer suscepti-
bility.
Due to the complementary functional roles of COMT and
CCND1, we have also investigated the combined effect of
their genotypes in association with altered breast cancer
risk. Our results suggest a genetic cross-talk between the
medium and higher enzymatic activity allele combina-
tions of CCND1 and COMT in breast cancer develop-
ment. The biological relevance of this combined effect
between CCND1 and COMT polymorphisms can be
explained in regard to their common relationship with
estrogen. Here, we suggest that the reduced estrogen
metabolization by the negative feedback of high COMT
activity may result in increased levels of estrogen, which in
turn may lead to enhanced expression of CCND1. Given
that CCND1High (A) variant also encodes a more stable
form of the protein, thus the cells containing this combi-
nation will be under pressure for increased cell cycle pro-
gression and proliferation. However this needs to be
experimentally validated. Genetically, our findings sug-
gests that the individuals inheriting the combinations of
high activity COMT and CCND1 alleles have relatively
higher breast cancer risk probably due to simultaneous
reduction in estrogen metabolism, and increase in cell
proliferation.
The magnitude of the increased combined risk effect was
higher in Ontario compared to Finland; however a test for
trend supported the association of increased breast cancer
risk with increasing activity of both CCND1 and COMT
genotypes in both populations. Although the ORs associ-
ated with the "at-risk" genotype combinations were
slightly lower in Finland compared to Ontario, the confi-
dence intervals of the estimates overlap and therefore
there is no clear evidence of a difference between the two
populations.
Conclusion
In this study, we have shown a combined effect between
the two commonly occurring polymorphisms associated
with higher enzymatic activity of CCND1 and COMT in
the context of breast cancer predisposition. The results of
this study also supports our initial findings where SNP-
SNP interactions between these polymorphisms was
observed in the subset of the Ontario sample [19]. About
90% of the cases and all of the controls from our initial
study [19] were also included in the Ontario sample. The
allelic frequencies of cases and controls for COMT and
CCND1 were identical in both studies. Our findings sug-BMC Cancer 2008, 8:6 http://www.biomedcentral.com/1471-2407/8/6
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gest that COMT and CCND1 alleles act in combination
and contribute to breast cancer progression. Here we pro-
pose that the allelic status of individuals with respect to
these two genes alters the relative risk of individuals for
breast cancer. This study provides an example of the
potential role of combined effect of SNPs with low pene-
trant alleles, and provides guidance to the understanding
of the genetic basis of breast cancer.
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